Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-gamma Agonist, Restores Alveolar and Pulmonary Vascular Development in a Rat Model of Bronchopulmonary Dysplasia
Yonsei Medical Journal
;
: 99-106, 2014.
Article
in English
| WPRIM
| ID: wpr-86935
ABSTRACT
PURPOSE:
We tested whether rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-gamma agonist, can restore alveolar development and vascular growth in a rat model of bronchopulmonary dysplasia (BPD). MATERIALS ANDMETHODS:
A rat model of BPD was induced through intra-amniotic delivery of lipopolysaccharide (LPS) and postnatal hyperoxia (80% for 7 days). RGZ (3 mg/kg/d, i.p.) or vehicle was given daily to rat pups for 14 days. This model included four experimental groups No BPD+vehicle (V), No BPD+RGZ, BPD+V, and BPD+RGZ. On D14, alveolarization, lung vascular density, and right ventricular hypertrophy (RVH) were evaluated.RESULTS:
Morphometric analysis revealed that the BPD+RGZ group had significantly smaller and more complex airspaces and larger alveolar surface area than the BPD+V group. The BPD+RGZ group had significantly greater pulmonary vascular density than the BPD+V group. Western blot analysis revealed that significantly decreased levels of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 by the combined exposure to intra-amniotic LPS and postnatal hyperoxia were restored by the RGZ treatment. RVH was significantly lesser in the BPD+RGZ group than in the BPD+V group.CONCLUSION:
These results suggest that RGZ can restore alveolar and pulmonary vascular development and lessen pulmonary hypertension in a rat model of BPD.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Vasodilator Agents
/
Bronchopulmonary Dysplasia
/
Immunohistochemistry
/
Rats, Sprague-Dawley
/
Thiazolidinediones
/
PPAR gamma
/
Hypertension, Pulmonary
/
Lung
Limits:
Animals
Language:
English
Journal:
Yonsei Medical Journal
Year:
2014
Type:
Article
Similar
MEDLINE
...
LILACS
LIS